Q-omics provides the consensus-scored PROB1 profile across patient tissues and cancer cell-line models. PROB1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PROB1 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, PROB1 RNA expression shows 20,190 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KICH, and ACC as cancer lineages where PROB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROB1 survival associations across molecular data types. PROB1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROB1 RNA expression–survival associations across cancer types. High PROB1 expression shows unfavorable associations in MESO, ACC and UVM, but favorable associations in SCLC, READ and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PROB1 RNA expression.
This table summarizes PROB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PROB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROB1 shows lower tumor expression in KICH, KIRP and COAD and higher tumor expression in LUAD, LUSC and LIHC. The KICH box plot shows higher PROB1 RNA expression in normal versus tumor tissue (log2 FC = −1.529, t-test p < 0.001).
This table shows molecular features associated with PROB1 in patient tissues and cancer cell lines. In patient samples, PROB1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PROB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
